Literature DB >> 21711992

Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection.

Onakewhor Joseph1, Olagbuji Biodun, Ezeanochie Michael.   

Abstract

OBJECTIVE: To evaluate adverse pregnancy outcome in HIV infected women who received highly active antiretroviral therapy (HAART) from early pregnancy compared with untreated-maternal HIV infection. STUDY
DESIGN: A cohort study. PLACE AND DURATION OF STUDY: Antenatal clinic, University of Benin Teaching Hospital, Nigeria, from January 2008 to June 2009.
METHODOLOGY: Two hundred and forty nine HIV infected women who had intrapartum care constituted the study population. Unbooked HIV positive pregnant women, who had not received antiretroviral drugs during the antenatal period but received nevirapine in labour, referred to as untreated-maternal HIV infection, were compared with women who received HAART early in pregnancy. Outcome measures of interest were obstetric complications and perinatal outcome proportion.
RESULTS: Intrauterine growth restriction (IUGR) (20.5% vs. 6.3%, p = 0.003), pre-term birth (25.0% vs. 9.8%, p = 0.005) and caesarean delivery (45.5% vs. 29.8%, p = 0.04) were significantly higher among women with untreated-HIV infection in pregnancy compared with women who received HAART from early pregnancy. Untreated maternal HIV-infection was associated with higher frequency of birth weight less than 2500g, 5-minutes Apgar score less than 7 and admission into neonatal unit (p < 0.05). Women with primary education were significantly higher in the group with untreated maternal HIV infection (27.3% vs. 12.7%, p = 0.003).
CONCLUSION: Untreated maternal HIV-infection in pregnancy may be associated with adverse pregnancy outcome. HIV positive women with low level of education utilise PMTCT services suboptimally. This information is important for programmes designed to increase access to PMTCT services including HAART from early pregnancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21711992     DOI: 07.2011/JCPSP.356359

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  6 in total

1.  Maternal post-absorptive leucine kinetics during late pregnancy in US women with HIV taking antiretroviral therapy: a cross-sectional pilot study.

Authors:  W Todd Cade; Gautam K Singh; Mark R Holland; Dominic N Reeds; E Turner Overton; Nancy Cibulka; Karen Bahow; Rachel Presti; Andrea Stephens; Alison G Cahill
Journal:  Clin Nutr ESPEN       Date:  2015-08-01

Review 2.  Maternal and child health interventions in Nigeria: a systematic review of published studies from 1990 to 2014.

Authors:  Musa Abubakar Kana; Henry Victor Doctor; Bárbara Peleteiro; Nuno Lunet; Henrique Barros
Journal:  BMC Public Health       Date:  2015-04-09       Impact factor: 3.295

3.  Characteristics and risk factors of preterm births in a tertiary center in Lagos, Nigeria.

Authors:  Azeez Butali; Chinyere Ezeaka; Osayame Ekhaguere; Nancy Weathers; Jenna Ladd; Iretiola Fajolu; Christopher Esezobor; Christian Makwe; Bukola Odusanya; Rose Anorlu; Wasiu Adeyemo; Edna Iroha; Mathias Egri-Okwaji; Prisca Adejumo; Lawal Oyeneyin; Moses Abiodun; Bolaji Badejoko; Kelli Ryckman
Journal:  Pan Afr Med J       Date:  2016-05-01

4.  Low birth weight and associated factors among HIV positive and negative mothers delivered in northwest Amhara region referral hospitals, Ethiopia,2020 a comparative crossectional study.

Authors:  Elsa Awoke Fentie; Hedija Yenus Yeshita; Moges Muluneh Bokie
Journal:  PLoS One       Date:  2022-02-11       Impact factor: 3.240

5.  Magnitudes and Correlates of Human Immunodeficiency Virus, Hepatitis B Virus, and Syphilis among Pregnant Mothers Attending Antenatal Care in Addis Ababa, Ethiopia.

Authors:  Kassa Genetu; Kerebih Abere; Erdaw Tachbele
Journal:  Infect Dis Obstet Gynecol       Date:  2022-02-16

Review 6.  Scoping review of maternal and newborn health interventions and programmes in Nigeria.

Authors:  Naima Nasir; Adeniyi Kolade Aderoba; Proochista Ariana
Journal:  BMJ Open       Date:  2022-02-15       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.